The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA Genetics’ AI platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world, they state. 

A precision medicine hub

The MOU envisions a precision medicine hub. For patients, the hub will act as an incubation studio for the discoveries of tomorrow, equipped with a deployment platform to quickly deliver new capabilities to patients worldwide. The hub could move new discoveries from bench to clinical care faster than traditional models, expanding access to MSK’s oncology intelligence for patients across the globe. For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.  

“This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge AI and robotics with the potential to transform cancer care at scale,” stated Michael G. Frank, Director of Digital Health Business Development at MSK.